Colin C. Geddes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Colin C. Geddes has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
Sokratis Stoumpos
Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK
4 shared publications- Alastair J. Rankin
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
3 shared publications - Bruce Mackinnon
Renal Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom
3 shared publications Emily P. McQuarrie
Glasgow Renal and Transplant Unit Queen Elizabeth University Hospital Glasgow UK
3 shared publicationsJonathan G. Fox
3 shared publications- Marc Clancy
Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, UK
3 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Ten tips on management of BK nephropathy in kidney transplant patients
Management of BK virus after kidney transplantation remains challenging, as recently published updated guidelines identify ongoing gaps in the evidence. In this article we present tips for management based on evidence and clinical experience. Testing blood for BK virus by polymerase chain reaction should be part of the workup for any patient with significant deterioration in kidney transplant function. All kidney transplant biopsies should be tested by immunohistochemistry for the presence of SV40 large T antigen if there are features of tubulointerstitial inflammation on light microscopy. A transplant kidney biopsy that does not include medulla does not exclude BK virus–associated nephropathy (BKVAN). Tubulointerstitial inflammation with positive SV40 staining and undetectable BK virus in the blood implies a different polyomavirus nephropathy such as JC virus. Clinicians should consider the evidence carefully before deciding whether or not to adopt a BK viraemia screening strategy in their unit. If a strategy of screening for BK viraemia in the absence of transplant dysfunction is adopted, then it makes sense to target the first year and for screening to be at least every 4 weeks. The optimal reduction in immunosuppression in response to BK viraemia or BKVAN has not been established by clinical trials. A rapid decline in BK viral load after reduction in immunosuppression appears to be a strong risk factor for impending T cell–mediated rejection. Clinical trials of the addition of potentially effective anti-polyomavirus agents including leflunomide, fluoroquinolones, intravenous immunoglobulin concentrate, cidofovir and statins have not shown benefit. BK viraemia or BKVAN recurrence after viral clearance is rare.
- 20 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Open AccessTen tips on management of BK nephropathy in kidney transplant patients
Management of BK virus after kidney transplantation remains challenging, as recently published updated guidelines identify ongoing gaps in the evidence. In this article we present tips for management based on evidence and clinical experience. Testing blood for BK virus by polymerase chain reaction should be part of the workup for any patient with significant deterioration in kidney transplant function. All kidney transplant biopsies should be tested by immunohistochemistry for the presence of SV40 large T antigen if there are features of tubulointerstitial inflammation on light microscopy. A transplant kidney biopsy that does not include medulla does not exclude BK virus–associated nephropathy (BKVAN). Tubulointerstitial inflammation with positive SV40 staining and undetectable BK virus in the blood implies a different polyomavirus nephropathy such as JC virus. Clinicians should consider the evidence carefully before deciding whether or not to adopt a BK viraemia screening strategy in their unit. If a strategy of screening for BK viraemia in the absence of transplant dysfunction is adopted, then it makes sense to target the first year and for screening to be at least every 4 weeks. The optimal reduction in immunosuppression in response to BK viraemia or BKVAN has not been established by clinical trials. A rapid decline in BK viral load after reduction in immunosuppression appears to be a strong risk factor for impending T cell–mediated rejection. Clinical trials of the addition of potentially effective anti-polyomavirus agents including leflunomide, fluoroquinolones, intravenous immunoglobulin concentrate, cidofovir and statins have not shown benefit. BK viraemia or BKVAN recurrence after viral clearance is rare.
- Open Access
- 23 June 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (7)
Major complications of percutaneous native and transplant kidney biopsy: a complete 10-year national prospective cohort study
Background: Previous reports of incidence of major complications (MC) of kidney biopsy vary depending on definitions of MC, single or multicentre analysis, and prospective or retrospective data collection. We aimed to provide accurate, unbiased information about the incidence of MC by analysing 10-year data from a prospective national renal biopsy registry. Methods: The Scottish Renal Biopsy Registry has prospectively collected data on all native and transplant kidney biopsies undertaken in the nine adult renal centres in Scotland since 2014. Nephrologists from each centre report demographics, operator, coded indication, coded diagnosis and coded MC. Results: A total of 8476 biopsies were reported in the 10 years between 2014 and 2023 (6167 native, 2309 transplant). The overall incidences of MC following native and transplant kidney biopsy were 2.1% and 1.4%, respectively (P < .001). The most common MC of native kidney biopsy was the requirement for ‘arteriography with embolization’ (0.63% of biopsies) and the most common MC of transplant biopsy was ‘blood transfusion only’ (0.30%). Nine deaths (0.15%) and no nephrectomies were attributed to native biopsy, and one death and one nephrectomy were attributed to transplant biopsy. MC were more common in women than men (2.2 vs 1.5%; P = .01). MC incidence was identical for biopsies performed by nephrologists (n = 5373) and radiologists (n = 2709). A positive association between quartile of serum creatinine at the time of native biopsy and incidence of MC diminished when acute kidney injury as indication for biopsy was excluded. Transplant biopsies >10 years after transplant had a higher risk of MC (3.4%). Conclusion: MC of kidney biopsy in the modern era remain rare. This registry analysis provides accurate estimates of risk based on unbiased national data. The increased incidence of MC in women merits further study.
- 23 June 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (7)
Open AccessMajor complications of percutaneous native and transplant kidney biopsy: a complete 10-year national prospective cohort study
Background: Previous reports of incidence of major complications (MC) of kidney biopsy vary depending on definitions of MC, single or multicentre analysis, and prospective or retrospective data collection. We aimed to provide accurate, unbiased information about the incidence of MC by analysing 10-year data from a prospective national renal biopsy registry. Methods: The Scottish Renal Biopsy Registry has prospectively collected data on all native and transplant kidney biopsies undertaken in the nine adult renal centres in Scotland since 2014. Nephrologists from each centre report demographics, operator, coded indication, coded diagnosis and coded MC. Results: A total of 8476 biopsies were reported in the 10 years between 2014 and 2023 (6167 native, 2309 transplant). The overall incidences of MC following native and transplant kidney biopsy were 2.1% and 1.4%, respectively (P < .001). The most common MC of native kidney biopsy was the requirement for ‘arteriography with embolization’ (0.63% of biopsies) and the most common MC of transplant biopsy was ‘blood transfusion only’ (0.30%). Nine deaths (0.15%) and no nephrectomies were attributed to native biopsy, and one death and one nephrectomy were attributed to transplant biopsy. MC were more common in women than men (2.2 vs 1.5%; P = .01). MC incidence was identical for biopsies performed by nephrologists (n = 5373) and radiologists (n = 2709). A positive association between quartile of serum creatinine at the time of native biopsy and incidence of MC diminished when acute kidney injury as indication for biopsy was excluded. Transplant biopsies >10 years after transplant had a higher risk of MC (3.4%). Conclusion: MC of kidney biopsy in the modern era remain rare. This registry analysis provides accurate estimates of risk based on unbiased national data. The increased incidence of MC in women merits further study.
- Open Access
- 18 January 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-10
The utility of split function testing in determining recovery of glomerular filtration rate after living kidney donation: a cohort study
A number of UK transplantation centres use isotope studies to estimate the relative contribution from each kidney in living kidney donor assessment. The evidence that the estimation of pre-donation split function of the non-donated kidney influences post-donation renal recovery is limited. The aim of this study was to analyse whether, in the context of other donor factors, the split function of the non-donated kidney predicts the percentage recovery of glomerular filtration rate (GFR) at one-year post-donation. A retrospective cohort analysis was undertaken on 291 living kidney donors in the Glasgow Renal and Transplant Unit between 1st January 2011 and 1st June 2022. Univariable and multivariable linear regression analysis was used to analyse the impact of donor factors on recovery of renal function at one year relative to baseline isotope GFR (iGFR) or to estimated GFR (eGFR by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula). Sub-analyses of donor outcome (% recovery of iGFR and eGFR at one year) were undertaken using single-measures ANOVA and grouping of donors by pre-donation isotope uptake of the non-donated kidney. Median recovery of pre-donation GFR at 1 year was 70.0% (IQR 64.8-75.5). On linear regression analysis there was no significant association found between split function of the non-donated kidney and the percentage recovery of iGFR, although a small significant association was found for eGFR. There was no significant difference between mean iGFR or eGFR recovery on sub-analysis of donor outcomes. This study demonstrated no clinically important predictive relationship between percentage recovery of renal function at 1 year after living kidney donation and pre-donation split function within the range accepted for donation in our centre.
- 18 January 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-10
Open AccessThe utility of split function testing in determining recovery of glomerular filtration rate after living kidney donation: a cohort study
A number of UK transplantation centres use isotope studies to estimate the relative contribution from each kidney in living kidney donor assessment. The evidence that the estimation of pre-donation split function of the non-donated kidney influences post-donation renal recovery is limited. The aim of this study was to analyse whether, in the context of other donor factors, the split function of the non-donated kidney predicts the percentage recovery of glomerular filtration rate (GFR) at one-year post-donation. A retrospective cohort analysis was undertaken on 291 living kidney donors in the Glasgow Renal and Transplant Unit between 1st January 2011 and 1st June 2022. Univariable and multivariable linear regression analysis was used to analyse the impact of donor factors on recovery of renal function at one year relative to baseline isotope GFR (iGFR) or to estimated GFR (eGFR by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula). Sub-analyses of donor outcome (% recovery of iGFR and eGFR at one year) were undertaken using single-measures ANOVA and grouping of donors by pre-donation isotope uptake of the non-donated kidney. Median recovery of pre-donation GFR at 1 year was 70.0% (IQR 64.8-75.5). On linear regression analysis there was no significant association found between split function of the non-donated kidney and the percentage recovery of iGFR, although a small significant association was found for eGFR. There was no significant difference between mean iGFR or eGFR recovery on sub-analysis of donor outcomes. This study demonstrated no clinically important predictive relationship between percentage recovery of renal function at 1 year after living kidney donation and pre-donation split function within the range accepted for donation in our centre.
- 12 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 590-591
Balanced crystalloids in kidney transplantation: the unknown benefits following donation after circulatory arrest
- 12 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 590-591
Balanced crystalloids in kidney transplantation: the unknown benefits following donation after circulatory arrest
- 3 August 2024
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 26 (4) , 1224-1228
Incidence of fatal and non-fatal pulmonary thromboembolism after removal of tunnelled central venous haemodialysis catheters without ultrasound scan and anticoagulation
Background: Catheter related thrombosis is a common complication of tunnelled central venous catheter (TCVC) usage. There are concerns that TCVC removal could dislodge a thrombus to cause pulmonary thromboembolism (PE). The incidence of PE following TCVC removal is unclear and so the aim of this study was to investigate the incidence of PE and whether it is high enough to warrant screening with ultrasound with a view to systemic anticoagulation prior to TCVC removal. Methods: 1102 consecutive TCVC removals without ultrasound and systemic anticoagulation were included in this retrospective study. Data were extracted from electronic health records. Measures to identify PE events included: deaths, computed tomography pulmonary angiogram (CT-PA), isotope lung perfusion scans and D-dimers blood tests within 7 days of removal. Results: Of the 1102 TCVC removals, the mean age of patients was 56.9 years and 57.3% were male. The primary renal diagnosis for 24.5% of patients was diabetic nephropathy. There were seven deaths following removal, none of which had PE as a contributing cause on review of their clinical history and death certificates. Five CT-PAs and one isotope lung perfusion scan were carried out in the 7 days after TCVC removal and none had a positive finding of PE. Three patient had D-dimers measured in blood within 7 days and none of these patients were subsequently diagnosed with PE. Conclusions: There was no evidence of fatal or non-fatal PE’s occurring in the 7 days following TCVC removal. This would support the practice of removing TCVCs without the need for ultrasound screening and without a period of systemic anticoagulation.
- 3 August 2024
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 26 (4) , 1224-1228
Incidence of fatal and non-fatal pulmonary thromboembolism after removal of tunnelled central venous haemodialysis catheters without ultrasound scan and anticoagulation
Background: Catheter related thrombosis is a common complication of tunnelled central venous catheter (TCVC) usage. There are concerns that TCVC removal could dislodge a thrombus to cause pulmonary thromboembolism (PE). The incidence of PE following TCVC removal is unclear and so the aim of this study was to investigate the incidence of PE and whether it is high enough to warrant screening with ultrasound with a view to systemic anticoagulation prior to TCVC removal. Methods: 1102 consecutive TCVC removals without ultrasound and systemic anticoagulation were included in this retrospective study. Data were extracted from electronic health records. Measures to identify PE events included: deaths, computed tomography pulmonary angiogram (CT-PA), isotope lung perfusion scans and D-dimers blood tests within 7 days of removal. Results: Of the 1102 TCVC removals, the mean age of patients was 56.9 years and 57.3% were male. The primary renal diagnosis for 24.5% of patients was diabetic nephropathy. There were seven deaths following removal, none of which had PE as a contributing cause on review of their clinical history and death certificates. Five CT-PAs and one isotope lung perfusion scan were carried out in the 7 days after TCVC removal and none had a positive finding of PE. Three patient had D-dimers measured in blood within 7 days and none of these patients were subsequently diagnosed with PE. Conclusions: There was no evidence of fatal or non-fatal PE’s occurring in the 7 days following TCVC removal. This would support the practice of removing TCVCs without the need for ultrasound screening and without a period of systemic anticoagulation.
- 7 August 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 39 (2) , 328-340
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. Retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-hour proteinuria from SGLT2i initiation to 3,6,9,12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate(eGFR), proteinuria reduction by type of disease, and reduction of proteinuria ≥ 30% from SGLT2i initiation. Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8%, –10.5% at 3,6,9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as predictor of ≥ 30% proteinuria reduction (odds ratio for albumin < 3.5 g/dl: 0.53; 95%CI 0.30–0.91; p = 0.02). A slower eGFR decline was observed in patients achieving a ≥ 30% proteinuria reduction: –3.7 versus –5.3 ml/min/1.73m2/year (p = 0.001). The overall tolerance to SGLT2i was good. The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥ 30% proteinuria reduction.
- 7 August 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 39 (2) , 328-340
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. Retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-hour proteinuria from SGLT2i initiation to 3,6,9,12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate(eGFR), proteinuria reduction by type of disease, and reduction of proteinuria ≥ 30% from SGLT2i initiation. Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8%, –10.5% at 3,6,9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as predictor of ≥ 30% proteinuria reduction (odds ratio for albumin < 3.5 g/dl: 0.53; 95%CI 0.30–0.91; p = 0.02). A slower eGFR decline was observed in patients achieving a ≥ 30% proteinuria reduction: –3.7 versus –5.3 ml/min/1.73m2/year (p = 0.001). The overall tolerance to SGLT2i was good. The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥ 30% proteinuria reduction.
- 16 November 2021
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 34 (6) , 2173-2175
Efficacy and side effect profile of two CMV prophylaxis strategies in high and intermediate risk kidney transplant recipients – a multicentre national study
- 16 November 2021
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 34 (6) , 2173-2175
Efficacy and side effect profile of two CMV prophylaxis strategies in high and intermediate risk kidney transplant recipients – a multicentre national study
- Open Access
- 7 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2135
Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis
Acute tubulointerstitial nephritis (ATIN) is a common cause of acute kidney injury. Although haematuria is a risk factor for the development of renal disease, no previous study has analyzed the significance of haematuria in ATIN. Retrospective, observational analysis of 110 patients with biopsy-proven ATIN was conducted. Results: Haematuria was present in 66 (60%) ATIN patients. A higher percentage of ATIN patients with haematuria had proteinuria than patients without haematuria (89.4% vs. 59.1%, p = 0.001) with significantly higher levels of proteinuria (median (interquartile range) protein:creatinine ratio 902.70 (513–1492) vs. 341.00 (177–734) mg/g, p p = 0.02). Those patients with higher proteinuria were more likely to need renal replacement therapy (22.7 vs. 0%, p = 0.03) and to suffer relapse (4 vs. 0%, p = 0.03). At the end of follow up, haematuric ATIN patients had higher serum creatinine levels (3.19 ± 2.91 vs. 1.91 ± 1.17 mg/dL, p = 0.007), and a trend towards a higher need for acute dialysis (7 vs. 1%, p = 0.09) and renal replacement therapy (12.1 vs. 2.3%, p = 0.12). Haematuria is common in ATIN and it is associated with worse renal function outcomes.
- 7 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2135
Open AccessHematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis
Acute tubulointerstitial nephritis (ATIN) is a common cause of acute kidney injury. Although haematuria is a risk factor for the development of renal disease, no previous study has analyzed the significance of haematuria in ATIN. Retrospective, observational analysis of 110 patients with biopsy-proven ATIN was conducted. Results: Haematuria was present in 66 (60%) ATIN patients. A higher percentage of ATIN patients with haematuria had proteinuria than patients without haematuria (89.4% vs. 59.1%, p = 0.001) with significantly higher levels of proteinuria (median (interquartile range) protein:creatinine ratio 902.70 (513–1492) vs. 341.00 (177–734) mg/g, p p = 0.02). Those patients with higher proteinuria were more likely to need renal replacement therapy (22.7 vs. 0%, p = 0.03) and to suffer relapse (4 vs. 0%, p = 0.03). At the end of follow up, haematuric ATIN patients had higher serum creatinine levels (3.19 ± 2.91 vs. 1.91 ± 1.17 mg/dL, p = 0.007), and a trend towards a higher need for acute dialysis (7 vs. 1%, p = 0.09) and renal replacement therapy (12.1 vs. 2.3%, p = 0.12). Haematuria is common in ATIN and it is associated with worse renal function outcomes.
- 6 December 2019
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 24, 625-630
Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
BACKGROUND Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients. The optimal duration of prophylaxis is unknown. Longer duration of prophylaxis may increase the risk of adverse effects. The aim of this retrospective observational cohort study was to assess the impact of increasing duration of TMP-SMX prophylaxis from 3 to 6 months after transplant on drug-resistant urinary tract infection (UTI), hyperkalemia, peripheral blood cytopenias, and incidence of PCP. MATERIAL AND METHODS Patients transplanted over a 4.5-year period before and after a change in protocol from 3- to 6-months TMP-SMX prophylaxis in our unit were grouped according to planned duration of prophylaxis, and results were analyzed on an intention-to-treat basis. Baseline characteristics, laboratory values, and all urine microbiology results in the 6 months after transplant were analyzed. RESULTS The overall UTI incidence rate was higher in the 3-month (3-m) treatment group than the 6-month (6-m) treatment group (0.52 vs. 0.33 UTI per 100 patient days; rate ratio 1.56 [95% CI 1.27-1.95]). However, this was not attributable to TMP-SMX: the incidences were significantly different in months 0-3 but not months 4-6. Twenty-eight multi-resistant UTIs occurred in the 3-m group, but there were none in the 6-m group (p=0.004). There were no significant differences in renal function, serum potassium, or cytopenias during the first 6 months. There were 15 cases of PCP in the 3-m group, 3 cases in the 6-m group, and no cases during prophylaxis. CONCLUSIONS Extending the duration of TMP-SMX prophylaxis was not associated with change in frequency of UTIs or multi-drug-resistant UTIs, nor was it associated with increased adverse events. TMP-SMX is an effective PCP prophylaxis, and these data support recommendations to extend the duration of prophylaxis after transplant.
- 6 December 2019
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 24, 625-630
Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
BACKGROUND Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients. The optimal duration of prophylaxis is unknown. Longer duration of prophylaxis may increase the risk of adverse effects. The aim of this retrospective observational cohort study was to assess the impact of increasing duration of TMP-SMX prophylaxis from 3 to 6 months after transplant on drug-resistant urinary tract infection (UTI), hyperkalemia, peripheral blood cytopenias, and incidence of PCP. MATERIAL AND METHODS Patients transplanted over a 4.5-year period before and after a change in protocol from 3- to 6-months TMP-SMX prophylaxis in our unit were grouped according to planned duration of prophylaxis, and results were analyzed on an intention-to-treat basis. Baseline characteristics, laboratory values, and all urine microbiology results in the 6 months after transplant were analyzed. RESULTS The overall UTI incidence rate was higher in the 3-month (3-m) treatment group than the 6-month (6-m) treatment group (0.52 vs. 0.33 UTI per 100 patient days; rate ratio 1.56 [95% CI 1.27-1.95]). However, this was not attributable to TMP-SMX: the incidences were significantly different in months 0-3 but not months 4-6. Twenty-eight multi-resistant UTIs occurred in the 3-m group, but there were none in the 6-m group (p=0.004). There were no significant differences in renal function, serum potassium, or cytopenias during the first 6 months. There were 15 cases of PCP in the 3-m group, 3 cases in the 6-m group, and no cases during prophylaxis. CONCLUSIONS Extending the duration of TMP-SMX prophylaxis was not associated with change in frequency of UTIs or multi-drug-resistant UTIs, nor was it associated with increased adverse events. TMP-SMX is an effective PCP prophylaxis, and these data support recommendations to extend the duration of prophylaxis after transplant.
- Open Access
- 5 November 2019
- Published by Wiley in Histopathology
- Vol. 76 (5) , 698-706
Predicting outcome in acute interstitial nephritis: a case–series examining the importance of histological parameters
Background The clinical significance of common histological parameters in acute interstitial nephritis (AIN) is uncertain. We aimed to evaluate the utility of histology in predicting clinical outcomes in patients with AIN. Methods and results Adult renal biopsies yielding a diagnosis of AIN between 2000 and 2015 were re‐examined. Patients were divided into groups based on: 1) the percentage of non‐fibrotic cortex containing inflammation (NFI‐score), (NFI‐1=0‐24%, NFI‐2=25‐74%, NFI‐3=75‐100%), and 2) the percentage of cortex containing tubular atrophy (TA score), (TA1=0‐9%, TA2=10‐24%, TA3=25‐100%). The primary outcome was a composite of ≥50% reduction in serum creatinine (sCr) or an eGFR >60 ml/min/1.73m2 1‐year post‐biopsy. From a total of 2817 native renal biopsies, there were 120 patients with AIN and adequate data for analysis. Of these, 66 (56%) achieved the primary outcome. On univariable logistic regression, NFI‐3 was associated with a 16 times increased likelihood of achieving the primary outcome compared to NFI‐1 (OR 16 (95% CI 5.2‐50)). In contrast, TA3 were associated with a 90% reduced likelihood of achieving the primary outcome compared to TA1 (OR=0.10 (95%CI 0.0‐0.3)). Maximal clinical utility was achieved by combining TA and NFI into a single prognostic ‘TANFI’ score, which had an independent predictive effect on the primary outcome in a multivariable regression model consisting of age, sex, baseline sCr and identified drug cause. Conclusions In patients with biopsy‐proven AIN, a lower percentage of cortical tubular atrophy and, paradoxically, a higher percentage of inflammation in non‐fibrosed cortex were associated with an increased likelihood of a positive clinical outcome.
- 5 November 2019
- Published by Wiley in Histopathology
- Vol. 76 (5) , 698-706
Open AccessPredicting outcome in acute interstitial nephritis: a case–series examining the importance of histological parameters
Background The clinical significance of common histological parameters in acute interstitial nephritis (AIN) is uncertain. We aimed to evaluate the utility of histology in predicting clinical outcomes in patients with AIN. Methods and results Adult renal biopsies yielding a diagnosis of AIN between 2000 and 2015 were re‐examined. Patients were divided into groups based on: 1) the percentage of non‐fibrotic cortex containing inflammation (NFI‐score), (NFI‐1=0‐24%, NFI‐2=25‐74%, NFI‐3=75‐100%), and 2) the percentage of cortex containing tubular atrophy (TA score), (TA1=0‐9%, TA2=10‐24%, TA3=25‐100%). The primary outcome was a composite of ≥50% reduction in serum creatinine (sCr) or an eGFR >60 ml/min/1.73m2 1‐year post‐biopsy. From a total of 2817 native renal biopsies, there were 120 patients with AIN and adequate data for analysis. Of these, 66 (56%) achieved the primary outcome. On univariable logistic regression, NFI‐3 was associated with a 16 times increased likelihood of achieving the primary outcome compared to NFI‐1 (OR 16 (95% CI 5.2‐50)). In contrast, TA3 were associated with a 90% reduced likelihood of achieving the primary outcome compared to TA1 (OR=0.10 (95%CI 0.0‐0.3)). Maximal clinical utility was achieved by combining TA and NFI into a single prognostic ‘TANFI’ score, which had an independent predictive effect on the primary outcome in a multivariable regression model consisting of age, sex, baseline sCr and identified drug cause. Conclusions In patients with biopsy‐proven AIN, a lower percentage of cortical tubular atrophy and, paradoxically, a higher percentage of inflammation in non‐fibrosed cortex were associated with an increased likelihood of a positive clinical outcome.